Financial Statements

Acer Therapeutics Inc. (ACER)

$0.6601

-0.14 (-17.95%)

Cash Flow Statement

All numbers are in thousands
Year XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
XLSX
2018
Operating Cash Flow -30,251.90-134.91-17,027.42-29,506.95-16,587.80
Net Income -26,237.31-15,373.99-22,885.45-29,417.97-21,280.89
Depreciation & Amortization 66.0370.9170.8158.2827.74
Deferred income taxes --122.58--
Stock-based compensation 1,840.502,287.012,224.152,612.861,318.15
Change in working capital -7,400.7413,450.073,081.26-2,817.703,347.19
Other non-cash items 1,479.63-568.91359.2357.58-
Investing Cash Flow -171.17-54.94-10.90-178.97-95.63
Investments in PPE -171.17-54.94-10.90-178.97-95.63
Financing Cash Flow 20,041.527,139.0510,722.2592.2742,710.36
Debt repayment -724.93----
Common Stock Issuance 8,909.723,139.0510,159.77-42,622.70
Other Financing Activites 11,856.744,000562.4892.2787.66
Accounts receivables 5,000-5,000---
Accounts payables 2,407.55-266.381,111.02-472.74937.96
Inventory --1,770.60---
Other working capital -14,808.2920,487.051,970.24-2,344.962,409.24
Cash at beginning of period 12,710.765,761.5712,077.6441,671.2815,644.35
Cash at end of period 2,329.2212,710.765,761.5712,077.6441,671.28
Capital Expenditure -171.17-54.94-10.90-178.97-95.63
Net cash flow / Change in cash -10,381.546,949.19-6,316.07-29,593.6426,026.93
Free Cash Flow -30,423.07-189.85-17,038.32-29,685.92-16,683.43

Acer Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Acer Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.